L50.9
Conditions
Interventions
Group 1: Telemedicine
Group 2: Face to Face visits
Sponsors
Novartis Pharma GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Written informed consent for participation obtained from the subject Diagnosed chronic spontaneous urticaria Medical therapy for CSU Concomitant chronic inducible urticaria is allowed Willing and be able to perform digital visits
Exclusion criteria
Exclusion criteria: simultaneous participation in any clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To quantitatively describe the frequency of UCT usage in CSU patients monitored via teledermatology compared to F2F visits. | — |
Secondary
| Measure | Time frame |
|---|---|
| To quantitatively describe the type and number of physician- patient interaction in both arms. | — |
Countries
Germany
Contacts
Public ContactAlexander Zink
Klinikum rechts der Isar
Outcome results
None listed